Skip to main content
Top
Published in: Journal of General Internal Medicine 9/2008

01-09-2008 | Original Article

Office-Based Management of Opioid Dependence with Buprenorphine: Clinical Practices and Barriers

Authors: Alexander Y. Walley, MD, MSc, Julie K. Alperen, DrPH, Debbie M. Cheng, ScD, Michael Botticelli, Carolyn Castro-Donlan, Jeffrey H. Samet, MD, MA, MPH, Daniel P. Alford, MD, MPH

Published in: Journal of General Internal Medicine | Issue 9/2008

Login to get access

Abstract

Background

Buprenorphine is a safe, effective and underutilized treatment for opioid dependence that requires special credentialing, known as a waiver, to prescribe in the United States.

Objective

To describe buprenorphine clinical practices and barriers among office-based physicians.

Design

Cross-sectional survey.

Participants

Two hundred thirty-five office-based physicians waivered to prescribe buprenorphine in Massachusetts.

Measurements

Questionnaires mailed to all waivered physicians in Massachusetts in October and November 2005 included questions on medical specialty, practice setting, clinical practices, and barriers to prescribing. Logistic regression analyses were used to identify factors associated with prescribing.

Results

Prescribers were 66% of respondents and prescribed to a median of ten patients. Clinical practices included mandatory counseling (79%), drug screening (82%), observed induction (57%), linkage to methadone maintenance (40%), and storing buprenorphine notes separate from other medical records (33%). Most non-prescribers (54%) reported they would prescribe if barriers were reduced. Being a primary care physician compared to a psychiatrist (AOR: 3.02; 95% CI: 1.48–6.18) and solo practice only compared to group practice (AOR: 3.01; 95% CI: 1.23–7.35) were associated with prescribing, while reporting low patient demand (AOR: 0.043, 95% CI: 0.009–0.21) and insufficient institutional support (AOR: 0.37; 95% CI: 0.15–0.89) were associated with not prescribing.

Conclusions

Capacity for increased buprenorphine prescribing exists among physicians who have already obtained a waiver to prescribe. Increased efforts to link waivered physicians with opioid-dependent patients and initiatives to improve institutional support may mitigate barriers to buprenorphine treatment. Several guideline-driven practices have been widely adopted, such as adjunctive counseling and monitoring patients with drug screening.
Literature
1.
go back to reference Center for Substance Abuse Treatment, Substance Abuse Treatment and Mental Health Services Administration, US Department of Health and Human Services. The determinations report: A report on the physician waiver program established by the Drug Addiction Treatment Act of 2000 (“DATA”). Available at: buprenorphine.samhsa.gov/SAMHSA_Determinations_Report.pdf. Accessed: May 16, 2008. Center for Substance Abuse Treatment, Substance Abuse Treatment and Mental Health Services Administration, US Department of Health and Human Services. The determinations report: A report on the physician waiver program established by the Drug Addiction Treatment Act of 2000 (“DATA”). Available at: buprenorphine.samhsa.gov/SAMHSA_Determinations_Report.pdf. Accessed: May 16, 2008.
2.
go back to reference Kakko J, Svanborg KD, Kreek MJ, Heilig M. One-year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: a randomised, placebo-controlled trial. Lancet. 2003;361(9358):662–8.PubMedCrossRef Kakko J, Svanborg KD, Kreek MJ, Heilig M. One-year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: a randomised, placebo-controlled trial. Lancet. 2003;361(9358):662–8.PubMedCrossRef
3.
go back to reference Alford DP, LaBelle CT, Richardson JM, et al. Treating homeless opioid dependent patients with buprenorphine in an office-based setting. J Gen Intern Med. 2007;22(2):171–6.PubMedCrossRef Alford DP, LaBelle CT, Richardson JM, et al. Treating homeless opioid dependent patients with buprenorphine in an office-based setting. J Gen Intern Med. 2007;22(2):171–6.PubMedCrossRef
4.
go back to reference Stein MD, Cioe P, Friedmann PD. Buprenorphine retention in primary care. J Gen Intern Med. 2005;20(11):1038–41.PubMedCrossRef Stein MD, Cioe P, Friedmann PD. Buprenorphine retention in primary care. J Gen Intern Med. 2005;20(11):1038–41.PubMedCrossRef
5.
go back to reference Mintzer IL, Eisenberg M, Terra M, MacVane C, Himmelstein DU, Woolhandler S. Treating opioid addiction with buprenorphine-naloxone in community-based primary care settings. Ann Fam Med. 2007;5(2):146–50.PubMedCrossRef Mintzer IL, Eisenberg M, Terra M, MacVane C, Himmelstein DU, Woolhandler S. Treating opioid addiction with buprenorphine-naloxone in community-based primary care settings. Ann Fam Med. 2007;5(2):146–50.PubMedCrossRef
6.
go back to reference Magura S, Lee SJ, Salsitz EA, et al. Outcomes of buprenorphine maintenance in office-based practice. J Addict Dis. 2007;26(2):13–23.PubMedCrossRef Magura S, Lee SJ, Salsitz EA, et al. Outcomes of buprenorphine maintenance in office-based practice. J Addict Dis. 2007;26(2):13–23.PubMedCrossRef
7.
go back to reference Mattick RP, Kimber J, Breen C, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2004;(3):CD002207 Mattick RP, Kimber J, Breen C, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2004;(3):CD002207
8.
go back to reference Johnson RE, Jaffe JH, Fudala PJ. A controlled trial of buprenorphine treatment for opioid dependence. JAMA. 1992;267(20):2750–5.PubMedCrossRef Johnson RE, Jaffe JH, Fudala PJ. A controlled trial of buprenorphine treatment for opioid dependence. JAMA. 1992;267(20):2750–5.PubMedCrossRef
9.
go back to reference Johnson RE, Chutuape MA, Strain EC, Walsh SL, Stitzer ML, Bigelow GE. A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence. N Engl J Med. 2000;343(18):1290–7.PubMedCrossRef Johnson RE, Chutuape MA, Strain EC, Walsh SL, Stitzer ML, Bigelow GE. A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence. N Engl J Med. 2000;343(18):1290–7.PubMedCrossRef
10.
go back to reference Fudala PJ, Bridge TP, Herbert S, et al. Office-Based Treatment of Opiate Addiction with a Sublingual-Tablet Formulation of Buprenorphine and Naloxone. N Engl J Med. 2003;349(10):949–8.PubMedCrossRef Fudala PJ, Bridge TP, Herbert S, et al. Office-Based Treatment of Opiate Addiction with a Sublingual-Tablet Formulation of Buprenorphine and Naloxone. N Engl J Med. 2003;349(10):949–8.PubMedCrossRef
11.
go back to reference O'Connor PG, Carroll KM, Shi JM, Schottenfeld RS, Kosten TR, Rounsaville BJ. Three Methods of Opioid Detoxification in a Primary Care Setting: A Randomized Trial. Ann Intern Med. 1997;127(7):526–30.PubMed O'Connor PG, Carroll KM, Shi JM, Schottenfeld RS, Kosten TR, Rounsaville BJ. Three Methods of Opioid Detoxification in a Primary Care Setting: A Randomized Trial. Ann Intern Med. 1997;127(7):526–30.PubMed
12.
go back to reference Ling W, Charuvastra C, Collins JF, et al. Buprenorphine maintenance treatment of opiate dependence: a multicenter, randomized clinical trial. Addiction. 1998;93(4):475–486.PubMedCrossRef Ling W, Charuvastra C, Collins JF, et al. Buprenorphine maintenance treatment of opiate dependence: a multicenter, randomized clinical trial. Addiction. 1998;93(4):475–486.PubMedCrossRef
13.
go back to reference Drug Addiction Treatment Act of 2000. Public Law 106–310, Page 114 STAT.1101-Page 114 STAT.1227. 8-2-0005. Drug Addiction Treatment Act of 2000. Public Law 106–310, Page 114 STAT.1101-Page 114 STAT.1227. 8-2-0005.
14.
go back to reference Center for Substance Abuse Treatment. Clinical guidelines for the use of buprenorphine in the treatment of opioid addiction. Treatment Improvement Protocol (TIP) Series 40.DHHS Publication No. (SMA) 04–3939. 2004. Rockville, MD. Center for Substance Abuse Treatment. Clinical guidelines for the use of buprenorphine in the treatment of opioid addiction. Treatment Improvement Protocol (TIP) Series 40.DHHS Publication No. (SMA) 04–3939. 2004. Rockville, MD.
16.
go back to reference Bivol, S. National poll of physicians on barriers to widespread buprenorphine use. 2003. Boston, Join Together. 8-29-2007. Bivol, S. National poll of physicians on barriers to widespread buprenorphine use. 2003. Boston, Join Together. 8-29-2007.
17.
go back to reference Kissin W, McLeod C, Sonnefeld J, Stanton A. Experiences of a national sample of qualified addiction specialists who have and have not prescribed buprenorphine for opioid dependence. J Addict Dis. 2006;25(4):91–103.PubMedCrossRef Kissin W, McLeod C, Sonnefeld J, Stanton A. Experiences of a national sample of qualified addiction specialists who have and have not prescribed buprenorphine for opioid dependence. J Addict Dis. 2006;25(4):91–103.PubMedCrossRef
19.
go back to reference West JC, Kosten TR, Wilk J, et al. Challenges in increasing access to buprenorphine treatment for opiate addiction. Am J Addict. 2004;13(Suppl 1):S8–S16.PubMedCrossRef West JC, Kosten TR, Wilk J, et al. Challenges in increasing access to buprenorphine treatment for opiate addiction. Am J Addict. 2004;13(Suppl 1):S8–S16.PubMedCrossRef
20.
go back to reference Wolinsky FD. Why physicians choose different types of practice settings. Health Serv Res. 1982;17(4):399–419.PubMed Wolinsky FD. Why physicians choose different types of practice settings. Health Serv Res. 1982;17(4):399–419.PubMed
21.
go back to reference Gaulier JM, Marquet P, Lacassie E, Dupuy JL, Lachatre G. Fatal intoxication following self-administration of a massive dose of buprenorphine. J Forensic Sci. 2000;45(1):226–8.PubMed Gaulier JM, Marquet P, Lacassie E, Dupuy JL, Lachatre G. Fatal intoxication following self-administration of a massive dose of buprenorphine. J Forensic Sci. 2000;45(1):226–8.PubMed
22.
go back to reference Becker WC, Fiellin DA. Provider satisfaction with office-based treatment of opioid dependence: a systematic review. Subst Abus. 2005;26(1):15–22.PubMedCrossRef Becker WC, Fiellin DA. Provider satisfaction with office-based treatment of opioid dependence: a systematic review. Subst Abus. 2005;26(1):15–22.PubMedCrossRef
23.
go back to reference Cunningham CO, Kunins HV, Roose RJ, Elam RT, Sohler NL. Barriers to obtaining waivers to prescribe buprenorphine for opioid addiction treatment among HIV physicians. J Gen Intern Med. 2007;22(9):1325–9.PubMedCrossRef Cunningham CO, Kunins HV, Roose RJ, Elam RT, Sohler NL. Barriers to obtaining waivers to prescribe buprenorphine for opioid addiction treatment among HIV physicians. J Gen Intern Med. 2007;22(9):1325–9.PubMedCrossRef
24.
go back to reference Turner BJ, Laine C, Lin YT, Lynch K. Barriers and facilitators to primary care or human immunodeficiency virus clinics providing methadone or buprenorphine for the management of opioid dependence. Arch Intern Med. 2005;165(15):1769–76.PubMedCrossRef Turner BJ, Laine C, Lin YT, Lynch K. Barriers and facilitators to primary care or human immunodeficiency virus clinics providing methadone or buprenorphine for the management of opioid dependence. Arch Intern Med. 2005;165(15):1769–76.PubMedCrossRef
Metadata
Title
Office-Based Management of Opioid Dependence with Buprenorphine: Clinical Practices and Barriers
Authors
Alexander Y. Walley, MD, MSc
Julie K. Alperen, DrPH
Debbie M. Cheng, ScD
Michael Botticelli
Carolyn Castro-Donlan
Jeffrey H. Samet, MD, MA, MPH
Daniel P. Alford, MD, MPH
Publication date
01-09-2008
Publisher
Springer-Verlag
Published in
Journal of General Internal Medicine / Issue 9/2008
Print ISSN: 0884-8734
Electronic ISSN: 1525-1497
DOI
https://doi.org/10.1007/s11606-008-0686-x

Other articles of this Issue 9/2008

Journal of General Internal Medicine 9/2008 Go to the issue